Zhi Tong Cai Jing·2026-03-24 21:21Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a slight decline in revenue for the fiscal year 2025, while net profit showed a modest increase, indicating mixed performance across its business segments [3]. Group 1: Financial Performance - The company achieved a revenue of RMB 575.168 billion, representing a year-on-year decrease of 1.6% [3]. - Net profit attributable to shareholders was RMB 7.155 billion, reflecting a year-on-year increase of 1.5% [3]. - Earnings per share were reported at RMB 2.29, with a proposed final dividend of RMB 0.69 per share [3]. Group 2: Business Segment Performance - The pharmaceutical distribution segment accounted for 72.79% of total revenue, showing a slight decline of 0.37 percentage points year-on-year [3]. - The medical device distribution segment contributed 19.32% to revenue, with a minor decrease of 0.09 percentage points year-on-year [3]. - The retail pharmaceutical segment's revenue share increased to 6.42%, up by 0.50 percentage points year-on-year [3]. Group 3: Market Outlook and Analyst Reactions - Citigroup's report indicated that the management expects the pharmaceutical distribution business sales to remain flat year-on-year, while medical device distribution and retail are anticipated to recover and show positive growth [3]. - Citigroup has revised its revenue forecasts for the company downwards by 3% and 4% for the next two years, reflecting the latest guidance from management [3]. - The earnings per share forecast was also adjusted downwards by 5% for both years, with the target price lowered from HKD 23 to HKD 22.8, while maintaining a "Buy" rating [3].